Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.
本发明涉及一种包含1号化合物(以I型形式存在)和固态分散物(包含基本无定形的2号化合物N-(5-羟基-2,4-二
叔丁基苯基)-4-氧代-1H-
喹啉-3-羧酰胺)的制药组合物,以及治疗、减轻或症状治疗CFTR介导的疾病(如囊性纤维化)的方法,制造方法,给药方法和相关工具包。